galcanezumab-gnlm
Trade name: emgality
mAbapproved
Approved
Sep 27, 2018
Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for the treatment of cluster headaches. — Wikipedia
Clinical trial activity
30 trials · 8 clinical orgs · 1 marketing orgs
Phase 1
6
Phase 2
17
Phase 3
12
Phase 4
7
Earliest trial started Apr 1, 2011 (NCT01337596)
Timeline
Indications
Mechanism of action
- Calcitonin gene-related peptide 1INHIBITOR
CALCA inhibitor
- Calcitonin gene-related peptideINHIBITOR
Calcitonin gene-related peptide inhibitor
- Calcitonin gene-related peptide 2Immunity, passive
CALCB immunity, passive
Approval history
- approvedSep 27, 2018
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaGalcanezumab ↗
- NCATS55KHL3P693 ↗
- ChEMBLCHEMBL3707328 ↗
Also known as
- galcanezumab
- galcanezumab
- galcanezumab-gnlm
- ly2951742
- ly-2951742
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05492695 | Phase 4 | Oct 1, 2022 | Diamond Headache Clinic |
| NCT05284019 | Phase 4 | Mar 4, 2022 | Lundbeck |
| NCT05127486 | Phase 4 | Nov 18, 2021 | Eli Lilly |
| NCT04616326 | Phase 3 | Nov 25, 2020 | Eli Lilly |
| NCT06901518 | Phase 4 | Aug 10, 2020 | Albany Medical College, Eli Lilly |
| NCT04417361 | Phase 2 | Jul 1, 2020 | Eli Lilly, University of California, San Francisco |
| NCT04294147 | Phase 4 | Mar 17, 2020 | Eli Lilly |
| NCT04271202 | Phase 4 | Mar 1, 2020 | Eli Lilly, Harvard University |
| NCT04158752 | Phase 4 | Dec 31, 2019 | Duke University, Eli Lilly |
| NCT04085289 | Phase 1 | Nov 14, 2019 | Eli Lilly |
| NCT04179474 | Phase 1 | Sep 26, 2019 | Allergan |
| NCT03963232 | Phase 3 | Jul 31, 2019 | Eli Lilly |
| NCT03559257 | Phase 3 | Jul 31, 2018 | Eli Lilly |
| NCT03432286 | Phase 3 | Mar 14, 2018 | Eli Lilly |
| NCT02959190 | Phase 3 | Feb 7, 2017 | Eli Lilly |
| NCT02959177 | Phase 2 | Nov 1, 2016 | Eli Lilly |
| NCT02836613 | Phase 1 | Jul 1, 2016 | Eli Lilly |
| NCT02797951 | Phase 3 | Jul 1, 2016 | Eli Lilly |
| NCT02614196 | Phase 3 | Dec 1, 2015 | Eli Lilly |
| NCT02614183 | Phase 3 | Nov 1, 2015 | Eli Lilly |
Showing 20 of 30 trials
Page 1 / 2
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 27 | 23 | 4 | 2011 |
| Albany Medical College | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Allergan | For profit | 1 | 1 | 1 | 2019 |
| Diamond Headache Clinic | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Lundbeck | For profit | 1 | 1 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2020 |
8 organizations
Page 1 / 1